Breast cancer imaging using radiolabelled somatostatin analogues
- 1 September 2016
- journal article
- review article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 43 (9) , 559-565
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and TherapyJournal of Nuclear Medicine, 2015
- Background 99mTc-methoxyisobutylisonitrile uptake of breast-specific gamma imaging in relation to background parenchymal enhancement in magnetic resonance imagingEuropean Radiology, 2014
- Biological subtypes of breast cancer: Prognostic and therapeutic implicationsWorld Journal of Clinical Oncology, 2014
- Current Breast Imaging Modalities, Advances, and Impact on Breast CareObstetrics and Gynecology Clinics of North America, 2013
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine TumorsEndocrinology and Metabolism Clinics of North America, 2011
- Screening for Breast Cancer: An Update for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2009
- SPECT/CTJournal of Nuclear Medicine, 2008
- Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue.Endocrine-Related Cancer, 2004
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989